Abbott Laboratories (ABT) - Healthcare Leader & Medical Technology Pioneer

Abbott Laboratories stands as a global healthcare leader that helps people live more fully at all stages of life. Founded in 1888 and headquartered in North Chicago, Illinois, the company has evolved into one of the world's most valuable healthcare corporations. As of September 2025, its market capitalization reached $231.37 billion USD, positioning it among the world's most valuable companies.

Company Overview

Abbott operates as a diversified healthcare company with a portfolio of life-changing technologies. It spans diagnostics, medical devices, nutritionals, and branded generic medicines, serving people in more than 160 countries through its 114,000 colleagues. The company's business model focuses on developing innovative healthcare solutions that improve patient outcomes across various medical conditions and life stages.

Business Segments

Abbott operates through four distinct segments:

- Established Pharmaceutical Products: Offers generic pharmaceuticals for conditions such as pancreatic exocrine insufficiency, hypertension, hypothyroidism, pain, inflammation, and more. This segment primarily focuses on international sales in emerging markets.

- Diagnostic Products: Provides laboratory and transfusion medicine systems, molecular diagnostics, point-of-care testing, and rapid diagnostics. It includes immunoassay, clinical chemistry, hematology, and transfusion serology testing systems. Prior to 2023, this was the largest revenue generator, dropping to around $9.3 billion USD in 2024.

- Nutritional Products: Supplies pediatric and adult nutritional products, including infant formula. Key products include Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, designed for people with diabetes. This segment also shows a growing market share in infant formula within the U.S.

- Medical Devices (Largest Segment): As of 2024, this was the largest segment, generating nearly $19 billion USD in revenues. It encompasses:

- Cardiovascular devices, diabetes care products, and neuromodulation devices for chronic pain and movement disorders.

- Heart failure, vascular, and structural heart devices.

- Glucose monitoring systems and diabetes management solutions.

Financial Performance

2024 Full Year Results

- Full-year 2024 sales totaled $42.0 billion, representing a 9.6% increase on an organic basis for the underlying base business (4.6% reported).

- Full-year adjusted diluted EPS was $4.67 (GAAP diluted EPS was $7.64).

- Abbott achieved the upper end of its initial guidance ranges for both organic sales growth and adjusted EPS provided in January 2024.

Q4 2024 Performance

- Fourth-quarter sales increased 10.1% on an organic basis (7.2% reported), totaling $11.0 billion.

- Growth was significantly driven by a 14.0% organic increase (13.7% reported) in Medical Devices, with both Diabetes Care and Structural Heart revenue growing over 20% in the quarter.

- Q4 adjusted diluted EPS was $1.34 (GAAP diluted EPS was $5.27), reflecting strong performance across all four business segments.

Investment Highlights

Dividend Aristocrat Status

Abbott maintains an exceptional dividend record, having increased its payout for 53 consecutive years. It is a member of the S&P 500 Dividend Aristocrats Index. The board declared a quarterly dividend of $0.59 per share, payable Feb. 14, 2025, to shareholders of record on Jan. 15, 2025.

Innovation and R&D

Continued investments in R&D in 2024 yielded over 15 new growth announcements from a productive pipeline. Notable innovations include the TriClip™ transcatheter edge-to-edge repair (TEER) system, a first-of-its-kind device to repair leaky tricuspid heart valves.

Strategic Partnerships

In August, Abbott announced a unique global partnership with Medtronic to collaborate on connecting Abbott's continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices.

2025 Financial Outlook

The company has issued the following full-year guidance for 2025:

- Non-GAAP operating margin: 23.5% to 24.0% of sales (reflecting a 150 basis point increase at the midpoint).

- Adjusted diluted EPS: $5.05 to $5.25 (reflecting double-digit growth at the midpoint).

- Organic sales growth: Projected to be in the range of 7.5% to 8.5%.

Capital Allocation

In October, Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares. This demonstrates a strong commitment to returning value to shareholders while maintaining robust growth investments.

Abbott Laboratories continues to solidify its position as a healthcare industry leader through consistent financial performance, innovative product development, and a proven track record of shareholder returns. The company's diversified portfolio across four key healthcare segments provides stability and significant growth opportunities within the expanding global healthcare market.